Total Funding
31
2
Total FundingVenture - Series Unknown raised
Growth Score 31 in past quarter
-2 pts
Heat Score 2 in past quarter
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
729376
Axikin Pharmaceuticals develops small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases.
Fred Middleton: Director
Peter McWilliams, Ph.D.: Chairman and Acting Chief Executive OfficerPast Role: Sanderling Ventures, Managing Director
About the Company
Axikin Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused exclusively on the development and commercialization of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease and
rheumatoid arthritis. Axikin was spun out from Actimis Pharmaceuticals, in June 2008.

